NeRRe Therapeutics Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
5
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:2
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (60.0%)Phase 1
2 (40.0%)Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
Phase 2
Completed
- Conditions
- CoughIdiopathic Pulmonary Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Nerre Therapeutics Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05185089
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸University of California, San Francisco, California, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
Mass Balance Study of [14C]-Orvepitant Oral Solution in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C]-orvepitant
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Nerre Therapeutics Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04387981
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
A Pharmacokinetic Study of the Effect of Itraconazole Exposure to Orvepitant in Healthy Volunteers
Phase 1
Completed
- Conditions
- Pharmacokinetic Study in Healthy Male Volunteers
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Nerre Therapeutics Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03535662
- Locations
- 🇬🇧
Parexel Epcu, Harrow, Middlesex, United Kingdom
A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Nerre Therapeutics Ltd.
- Registration Number
- NCT03464526
A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough
Phase 2
Completed
- Conditions
- Chronic Refractory Cough
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Nerre Therapeutics Ltd.
- Target Recruit Count
- 315
- Registration Number
- NCT02993822
- Locations
- 🇺🇸
Study Site 15, Chandler, Arizona, United States
🇺🇸Study Site 43, Los Angeles, California, United States
🇺🇸Study Site 52, Mission Viejo, California, United States
News
No news found